herbalife ltd. - HLF
HLF
Close Chg Chg %
8.56 0.07 0.82%
Closed Market
8.63
+0.07 (0.82%)
Volume: 2.14M
Last Updated:
Mar 31, 2025, 3:59 PM EDT
Company Overview: herbalife ltd. - HLF
HLF Key Data
| Open $8.53 | Day Range 8.16 - 8.85 |
| 52 Week Range 5.04 - 12.79 | Market Cap $867.26M |
| Shares Outstanding 101.20M | Public Float 98.46M |
| Beta 1.03 | Rev. Per Employee N/A |
| P/E Ratio 3.42 | EPS $2.52 |
| Yield 0.00% | Dividend $0.30 |
| EX-DIVIDEND DATE Feb 28, 2014 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.97M |
HLF Performance
| 1 Week | 0.00% | ||
| 1 Month | 3.25% | ||
| 3 Months | 28.10% | ||
| 1 Year | -14.73% | ||
| 5 Years | -70.83% |
HLF Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About herbalife ltd. - HLF
Herbalife Ltd. is a holding company, which engages in the provision of health and wellness products. It operates through the following geographical segments: North America, Latin America, EMEA, Asia Pacific, and China. The company was founded by Mark Reynolds Hughes in February 1980 and is headquartered in Los Angeles, CA.
HLF At a Glance
Herbalife Ltd.
800 West Olympic Boulevard
Los Angeles, California 90015
| Phone | N/A | Revenue | 4.99B | |
| Industry | Medical Distributors | Net Income | 254.30M | |
| Sector | Distribution Services | Employees | 8,600 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
HLF Valuation
| P/E Current | 3.424 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 2.673 |
| Price to Sales Ratio | 0.136 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 2.382 |
| Enterprise Value to EBITDA | 4.773 |
| Enterprise Value to Sales | 0.547 |
| Total Debt to Enterprise Value | 0.905 |
HLF Efficiency
| Revenue/Employee | 580,593.023 |
| Income Per Employee | 29,569.767 |
| Receivables Turnover | 65.959 |
| Total Asset Turnover | 1.803 |
HLF Liquidity
| Current Ratio | 0.93 |
| Quick Ratio | 0.543 |
| Cash Ratio | 0.341 |
HLF Profitability
| Gross Margin | 75.841 |
| Operating Margin | 9.022 |
| Pretax Margin | 3.393 |
| Net Margin | 5.093 |
| Return on Assets | 9.185 |
| Return on Equity | N/A |
| Return on Total Capital | 15.244 |
| Return on Invested Capital | 18.801 |
HLF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 148.022 |
| Total Debt to Total Assets | 90.514 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 128.648 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Herbalife Ltd. - HLF
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 5.80B | 5.20B | 5.06B | 4.99B | |
Sales Growth
| +4.71% | -10.31% | -2.73% | -1.37% | |
Cost of Goods Sold (COGS) incl D&A
| 1.32B | 1.26B | 1.28B | 1.21B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 107.60M | 115.40M | 113.30M | 121.40M | |
Depreciation
| 89.20M | 94.30M | 88.90M | 96.50M | |
Amortization of Intangibles
| 18.40M | 21.10M | 24.40M | 24.90M | |
COGS Growth
| +7.31% | -5.06% | +2.02% | -5.89% | |
Gross Income
| 4.48B | 3.95B | 3.78B | 3.79B | |
Gross Income Growth
| +3.97% | -11.86% | -4.24% | +0.16% | |
Gross Profit Margin
| +77.19% | +75.86% | +74.68% | +75.84% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 3.75B | 3.41B | 3.46B | 3.34B | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 3.75B | 3.41B | 3.46B | 3.34B | |
SGA Growth
| +5.19% | -8.98% | +1.42% | -3.59% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 36.00M | (500.00K) | (1.60M) | 90.50M | |
EBIT after Unusual Expense
| 694.80M | 536.60M | 321.70M | 360.00M | |
Non Operating Income/Expense
| 18.20M | 27.70M | 47.20M | 27.70M | |
Non-Operating Interest Income
| 4.40M | 6.10M | 11.50M | 12.30M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 152.20M | 139.50M | 166.20M | 218.30M | |
Interest Expense Growth
| +14.87% | -8.34% | +19.14% | +31.35% | |
Gross Interest Expense
| 152.20M | 139.50M | 166.20M | 218.30M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 560.80M | 424.80M | 203.00M | 169.40M | |
Pretax Income Growth
| +8.60% | -24.25% | -52.21% | -16.55% | |
Pretax Margin
| +9.66% | +8.16% | +4.01% | +3.39% | |
Income Tax
| 113.60M | 103.50M | 60.80M | (84.90M) | |
Income Tax - Current - Domestic
| 25.10M | 33.30M | 21.10M | 54.40M | |
Income Tax - Current - Foreign
| 121.80M | 100.10M | 80.80M | 90.30M | |
Income Tax - Deferred - Domestic
| (16.30M) | (27.90M) | (39.40M) | (63.70M) | |
Income Tax - Deferred - Foreign
| (17.00M) | (2.00M) | (1.70M) | (165.90M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 447.20M | 321.30M | 142.20M | 254.30M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 447.20M | 321.30M | 142.20M | 254.30M | |
Net Income Growth
| +20.02% | -28.15% | -55.74% | +78.83% | |
Net Margin Growth
| +7.71% | +6.17% | +2.81% | +5.09% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 447.20M | 321.30M | 142.20M | 254.30M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 447.20M | 321.30M | 142.20M | 254.30M | |
EPS (Basic)
| 4.2228 | 3.2619 | 1.4364 | 2.5278 | |
EPS (Basic) Growth
| +49.03% | -22.76% | -55.96% | +75.98% | |
Basic Shares Outstanding
| 105.90M | 98.50M | 99.00M | 100.60M | |
EPS (Diluted)
| 4.1293 | 3.2292 | 1.4192 | 2.5029 | |
EPS (Diluted) Growth
| +49.06% | -21.80% | -56.05% | +76.36% | |
Diluted Shares Outstanding
| 108.30M | 99.50M | 100.20M | 101.60M | |
EBITDA
| 838.40M | 651.50M | 433.40M | 571.90M | |
EBITDA Growth
| -0.80% | -22.29% | -33.48% | +31.96% | |
EBITDA Margin
| +14.45% | +12.52% | +8.56% | +11.45% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 8.875 | |
| Number of Ratings | 5 | Current Quarters Estimate | 0.596 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | 1.954 | |
| Last Quarter’s Earnings | 0.406 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.96 | Next Fiscal Year Estimate | 2.424 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 4 | 4 |
| Mean Estimate | 0.60 | 0.48 | 1.95 | 2.42 |
| High Estimates | 0.62 | 0.55 | 2.10 | 2.71 |
| Low Estimate | 0.57 | 0.43 | 1.78 | 2.16 |
| Coefficient of Variance | 4.20 | 12.98 | 7.48 | 9.85 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 1 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 3 | 4 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Hold | Hold |
SEC Filings for Herbalife Ltd. - HLF
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Herbalife Ltd. - HLF
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 7, 2025 | Juan Miguel Mendoza Director | 135,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $8 per share | 1,080,000.00 |
| Feb 26, 2025 | Troy Hicks Chief Operating Officer | 56,447 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.29 per share | 467,945.63 |
| Feb 26, 2025 | Michael O. Johnson Chairman & CEO; Director | 442,477 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Henry C. Wang Chief Legal Officer | 77,433 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Henry C. Wang Chief Legal Officer | 159,517 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.29 per share | 1,322,395.93 |
| Feb 26, 2025 | Stephan Paulo Gratziani President | 309,734 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Jehangir D. Irani SVP, PAO | 64,459 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.29 per share | 534,365.11 |
| Feb 26, 2025 | Troy Hicks Chief Operating Officer | 52,445 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | John G. DeSimone Chief Financial Officer | 258,526 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.29 per share | 2,143,180.54 |
| May 13, 2024 | Juan Miguel Mendoza Director | 93,279 | Open market or private purchase of non-derivative security Non-derivative transaction at $10.65 per share | 993,421.35 |
| May 13, 2024 | Juan Miguel Mendoza Director | 86,279 | Open market or private purchase of non-derivative security Non-derivative transaction at $10.59 per share | 913,694.61 |
| May 8, 2024 | Ibelis Inglewood Fleming EVP & Chief of Staff | 151,821 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 8, 2024 | Sophie L'Hélias Director | 43,746 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 8, 2024 | Frank Lamberti Chief Operating Officer | 212,550 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 8, 2024 | Frank Lamberti Chief Operating Officer | 248,838 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $9.58 per share | 2,383,868.04 |
| May 8, 2024 | Frank Lamberti Chief Operating Officer | 250,857 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 8, 2024 | Ibelis Inglewood Fleming EVP & Chief of Staff | 160,812 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $9.58 per share | 1,540,578.96 |
| May 8, 2024 | Ibelis Inglewood Fleming EVP & Chief of Staff | 162,831 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 8, 2024 | Richard H. Carmona Director | 49,909 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 8, 2024 | María Otero Director | 58,193 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |